- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04339270
Krooniset hengitystiesairaudet, liman reologia ja pahenemisvaiheet (COPD-CARhE)
Krooniset hengitystiesairaudet, liman reologia ja pahenemisvaiheet: satunnaistettu kontrolloitu tutkimus COPD-potilailla
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
The secondary objectives are to compare between the 2 arms:
- exacerbation number according to their severity (observed throughout the duration of the study);
- the evolution of the symptoms, the rheology of the sputum, and the pulmonary function (measurements repeated every three months);
- medication consumption and adverse events (monitored throughout the duration of the study);
- patient trajectories during follow-up;
- the overall clinical improvement at the end of the study and the evolution of the quality of life (measurements repeated every 3 months);
- the change in biomarkers of interest (baseline versus end of study).
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 4
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Jérémy Charriot, MD
- Puhelinnumero: 04 67 33 67 33
- Sähköposti: j-charriot@chu-montpellier.fr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Arnaud BOURDIN, MD
- Puhelinnumero: 04 67 33 67 33
- Sähköposti: a-bourdin@chu-montpellier.fr
Opiskelupaikat
-
-
-
Bordeaux, Ranska
- Rekrytointi
- University Hospitals of Bordeaux
-
Päätutkija:
- Maéva Zysman, MD, PhD
-
Montpellier, Ranska, 34925
- Rekrytointi
- University Hospitals of Montpellier
-
Päätutkija:
- Jérémy Charriot, MD
-
Alatutkija:
- Arnaud Bourdin, MD, PhD
-
Alatutkija:
- Anne-Sophie Gamez, MD
-
Alatutkija:
- Jean Romain, MD
-
Toulouse, Ranska
- Rekrytointi
- University Hospitals of Toulouse
-
Päätutkija:
- Laurent Guilleminault, MD
-
Alatutkija:
- Alain Didier, MD, PhD
-
Alatutkija:
- Danielle Brouquieres, MD
-
Alatutkija:
- Nicolas Guibert, MD
-
Alatutkija:
- Sandrine Pontier Marchandise, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Subjets between 40 - 85 years (included)
- Written and signed informed consent form
- Subjects must be able to attend all planned visits and comply with all test procedures
- Beneficiary of or affiliated with the French social security system
- Man or woman with chronic obstructive pulmonary disease for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator
- Optimal treatment according to GOLD class severity C or D recommendations
- >=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months
- Spontaneous or induced sputum production
- Electrocardiogram: corrected distance between Q and T waves (QTC) <450 ms in men, QTC <470 ms in women
- Normal audiogram for age or absence of contraindication to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion
Exclusion Criteria:
- Pregnancy or breastfeeding
- Patients who are prisoners or under other forms of judicial protection
- Patients under any form of guardianship
- Participation in another interventional protocol, (current or during the month preceding inclusion)
- Received azithromycin in the past 3 months
- Patient whose primary diagnosis is bronchial dilation based on CT scan documentation
- Known hypersensitivity to azithromycin, erythromycin, any other macrolide, ketolide or any of the excipients of the azithromycin-based specialty used
- Concomitant use of medication contraindicated with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine)
- Other respiratory diseases or associated lung infections
- Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion)
- Renal impairment with creatinine clearance < 40 mL/min
- Patients with hematological malignancies who have undergone allogeneic hematopoietic stem cell transplantation
- Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Azithromycin according to symptoms
Patients randomized to this arm will be prescribed azithromycin in function of their symptoms. |
Patients randomized to the "standardized comparator arm" will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score <70 to homogenize practices between centers). CASA-Q will be evaluated every 3 months.
|
|
Kokeellinen: Azithromycin according to rheology
Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology. |
Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score <70). The rheology of mucus will be quantified every 3 months.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
The main outcome measure is the number of exacerbations over the 12 months of follow-up.
Aikaikkuna: 12 months
|
An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond [normal] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)." |
12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Reologia: liman kimmokerroin (G')
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Reologia: liman kimmokerroin (G')
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Reologia: liman kimmokerroin (G')
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Reologia: liman kimmokerroin (G')
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Reologia: liman kimmokerroin (G')
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Reologia: viskoosi moduuli (G '')
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Reologia: viskoosi moduuli (G '')
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Reologia: viskoosi moduuli (G '')
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Reologia: viskoosi moduuli (G '')
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Reologia: viskoosi moduuli (G '')
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Reologia: suhde G '' / G '
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Reologia: suhde G '' / G '
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Reologia: suhde G '' / G '
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Reologia: suhde G '' / G '
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Reologia: suhde G '' / G '
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Reologia: kriittinen rajoite (tau-C).
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Reologia: kriittinen rajoite (tau-C).
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Reologia: kriittinen rajoite (tau-C).
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Reologia: kriittinen rajoite (tau-C).
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Reologia: kriittinen rajoite (tau-C).
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Spirometria: pakotettu uloshengitystilavuus 1 minuutissa (FEV1)
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Spirometria: pakotettu uloshengitystilavuus 1 minuutissa (FEV1)
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Spirometria: pakotettu uloshengitystilavuus 1 minuutissa (FEV1)
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Spirometria: pakotettu uloshengitystilavuus 1 minuutissa (FEV1)
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Spirometria: pakotettu uloshengitystilavuus 1 minuutissa (FEV1)
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Spirometria: pakotettu vitaalikapasiteetti (FVC)
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Spirometria: pakotettu vitaalikapasiteetti (FVC)
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Spirometria: pakotettu vitaalikapasiteetti (FVC)
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Spirometria: pakotettu vitaalikapasiteetti (FVC)
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Spirometria: pakotettu vitaalikapasiteetti (FVC)
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Spirometria: FEV1/FVC
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Spirometria: FEV1/FVC
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Spirometria: FEV1/FVC
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Spirometria: FEV1/FVC
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Spirometria: FEV1/FVC
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: jäännöstilavuus (RV)
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Pletysmografia keuhkojen tilavuudelle: jäännöstilavuus (RV)
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: jäännöstilavuus (RV)
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: jäännöstilavuus (RV)
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: jäännöstilavuus (RV)
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Keuhkojen tilavuuksien pletysmografia: toiminnallinen jäännöskapasiteetti (FRC)
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Keuhkojen tilavuuksien pletysmografia: toiminnallinen jäännöskapasiteetti (FRC)
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Keuhkojen tilavuuksien pletysmografia: toiminnallinen jäännöskapasiteetti (FRC)
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Keuhkojen tilavuuksien pletysmografia: toiminnallinen jäännöskapasiteetti (FRC)
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Keuhkojen tilavuuksien pletysmografia: toiminnallinen jäännöskapasiteetti (FRC)
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: keuhkojen kokonaiskapasiteetti (TLC)
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Pletysmografia keuhkojen tilavuudelle: keuhkojen kokonaiskapasiteetti (TLC)
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: keuhkojen kokonaiskapasiteetti (TLC)
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: keuhkojen kokonaiskapasiteetti (TLC)
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuudelle: keuhkojen kokonaiskapasiteetti (TLC)
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuuksille: RV/TLC
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Pletysmografia keuhkojen tilavuuksille: RV/TLC
Aikaikkuna: 3 kuukautta
|
3 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuuksille: RV/TLC
Aikaikkuna: 6 kuukautta
|
6 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuuksille: RV/TLC
Aikaikkuna: 9 kuukautta
|
9 kuukautta
|
|
|
Pletysmografia keuhkojen tilavuuksille: RV/TLC
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Lääkkeiden kulutus koko tutkimuksen ajan.
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Haittavaikutusten määrä kirjataan koko tutkimuksen ajan.
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Serum Club -solujen eritysproteiini
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Serum Club -solujen eritysproteiini
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
Ysköksen bakteriologia
Aikaikkuna: Perustaso (päivä 0)
|
Perustaso (päivä 0)
|
|
|
Ysköksen bakteriologia
Aikaikkuna: 12 kuukautta
|
12 kuukautta
|
|
|
The number of mild exacerbations throughout follow-up
Aikaikkuna: 12 months
|
A mild exacerbation does not require new additional medicine. |
12 months
|
|
The number of moderate exacerbations throughout follow-up
Aikaikkuna: 12 months
|
Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization). |
12 months
|
|
The number of severe exacerbations throughout follow-up
Aikaikkuna: 12 months
|
Severe exacerbations require hospitalization. |
12 months
|
|
COPD Assessment Test (CAT)
Aikaikkuna: Baseline (Day 0)
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
Baseline (Day 0)
|
|
COPD Assessment Test (CAT)
Aikaikkuna: 3 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
3 months
|
|
COPD Assessment Test (CAT)
Aikaikkuna: 6 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
6 months
|
|
COPD Assessment Test (CAT)
Aikaikkuna: 9 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
9 months
|
|
COPD Assessment Test (CAT)
Aikaikkuna: 12 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
12 months
|
|
Sino Nasal Outcome Test 22
Aikaikkuna: Baseline (Day 0)
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
Baseline (Day 0)
|
|
Sino Nasal Outcome Test 22
Aikaikkuna: 3 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
3 months
|
|
Sino Nasal Outcome Test 22
Aikaikkuna: 6 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
6 months
|
|
Sino Nasal Outcome Test 22
Aikaikkuna: 9 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
9 months
|
|
Sino Nasal Outcome Test 22
Aikaikkuna: 12 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
12 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
Aikaikkuna: Baseline (Day 0)
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
Baseline (Day 0)
|
|
Cough and sputum assessment questionnaire (CASA-Q)
Aikaikkuna: 3 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
3 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
Aikaikkuna: 6 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
6 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
Aikaikkuna: 9 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
9 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
Aikaikkuna: 12 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
12 months
|
|
Visual analogue scale for dyspnea
Aikaikkuna: Baseline (Day 0)
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
Baseline (Day 0)
|
|
Visual analogue scale for dyspnea
Aikaikkuna: 3 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
3 months
|
|
Visual analogue scale for dyspnea
Aikaikkuna: 6 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
6 months
|
|
Visual analogue scale for dyspnea
Aikaikkuna: 9 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
9 months
|
|
Visual analogue scale for dyspnea
Aikaikkuna: 12 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
12 months
|
|
Visual analogue scale for coughing
Aikaikkuna: Baseline (Day 0)
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
Baseline (Day 0)
|
|
Visual analogue scale for coughing
Aikaikkuna: 3 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
3 months
|
|
Visual analogue scale for coughing
Aikaikkuna: 6 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
6 months
|
|
Visual analogue scale for coughing
Aikaikkuna: 9 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
9 months
|
|
Visual analogue scale for coughing
Aikaikkuna: 12 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
12 months
|
|
Visual analogue scale for sputum production
Aikaikkuna: Baseline (Day 0)
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
Baseline (Day 0)
|
|
Visual analogue scale for sputum production
Aikaikkuna: 3 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
3 months
|
|
Visual analogue scale for sputum production
Aikaikkuna: 6 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
6 months
|
|
Visual analogue scale for sputum production
Aikaikkuna: 9 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
9 months
|
|
Visual analogue scale for sputum production
Aikaikkuna: 12 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
12 months
|
|
Episodes of exacerbation throughout the study
Aikaikkuna: 12 months
|
For each exacerbation, the beginning and end dates will be recorded. |
12 months
|
|
Episodes of hospitalization throughout the study
Aikaikkuna: 12 months
|
For each hospitalization, the beginning and end dates will be recorded. |
12 months
|
|
Clinical improvement
Aikaikkuna: 12 months
|
Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows:
|
12 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
Aikaikkuna: Baseline (day 0)
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
Baseline (day 0)
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
Aikaikkuna: 3 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
3 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
Aikaikkuna: 6 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
6 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
Aikaikkuna: 9 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
9 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
Aikaikkuna: 12 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
12 months
|
|
EQ-5D-5L
Aikaikkuna: Baseline (day 0)
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
Baseline (day 0)
|
|
EQ-5D-5L
Aikaikkuna: 3 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
3 months
|
|
EQ-5D-5L
Aikaikkuna: 6 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
6 months
|
|
EQ-5D-5L
Aikaikkuna: 9 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
9 months
|
|
EQ-5D-5L
Aikaikkuna: 12 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
12 months
|
|
St-George's Respiratory Questionnaire
Aikaikkuna: Baseline (day 0)
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
Baseline (day 0)
|
|
St-George's Respiratory Questionnaire
Aikaikkuna: 3 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
3 months
|
|
St-George's Respiratory Questionnaire
Aikaikkuna: 6 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
6 months
|
|
St-George's Respiratory Questionnaire
Aikaikkuna: 9 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
9 months
|
|
St-George's Respiratory Questionnaire
Aikaikkuna: 12 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
12 months
|
|
Blood cell differential: neutrophil levels
Aikaikkuna: Baseline (day 0)
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
Baseline (day 0)
|
|
Blood cell differential: eosinophil levels
Aikaikkuna: Baseline (day 0)
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
Baseline (day 0)
|
|
Blood cell differential: neutrophil levels
Aikaikkuna: 12 months
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
12 months
|
|
Blood cell differential: eosinophil levels
Aikaikkuna: 12 months
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
12 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Opintojohtaja: Jérémy Charriot, MD, University Hospital, Montpellier
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- RECHMPL19_0074
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity.
Data will be made available to persons who address a reasonable request to the study director and fulfil the requirements stipulated by the French CNIL (Commission Nationale de l'Informatique et des Libertés : https://www.cnil.fr/professionnel).
IPD-jaon aikakehys
As close to "real time" as possible, the following supporting information will be made public:
- Study Protocol (to be published in an appropriate journal).
- Statistical Analysis Plan
- Participant Information materials
- Analytic code
These will be posted and registered on osf.io and/or clinicaltrials.gov (if not published).
Datasets can be requested after the publication process has been completed.
IPD-jaon käyttöoikeuskriteerit
The conditions under which members of the public will be granted access to datasets are:
- The data will be used/examined in a not-for-profit manner;
- The data will not be used in an attempt to identify a participant or group of participants;
- The user does not work for a private insurance company;
- The data will not be used in support of any kind of private insurance policy or health penalties;
- The data will be used/examined for the advancement of science/teaching while respecting participant/patient privacy and rights;
- The user will state why they wish to access the data.
- The appropriate CNIL approval has been obtained by the user.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .